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(%), (r 2  0.60; standard deviation  19 mL/min). Our resultsDeterminants of outcome in ANCA-associated glomerulo-
were independent of diagnosis, ANCA-specificity, and treat-nephritis: A prospective clinico-histopathological analysis of
ment limb.96 patients.
Conclusions. These data suggest that in ANCA-associatedBackground. The predictive value of clinical and renal histo-
glomerulonephritis, GFR0 and predominantly chronic renal le-logical features for renal outcome in patients with anti-neutro-
sions are potent predictors of GFR18. Active lesions are associ-phil cytoplasmic autoantibody (ANCA)-associated glomerulo-
ated with renal function recovery and may be reversible. Thenephritis was investigated in a prospective analysis of 96
formula for the estimation of GFR18 shows that a combinationpatients with ANCA-associated vasculitis, and moderate renal
of GFR0 and renal histology is a better predictor for GFR18involvement (creatinine 500 mol/L).
than GFR0 only.Methods. The extent of 39 histological features in 96 biop-
sies (performed at entry in a clinical trial) was scored by two
independent observers, according to a standardized protocol.
Age, gender, diagnosis, glomerular filtration rate at entry Rapidly progressive deterioration of renal function is(GFR0), ANCA-specificity, proteinuria, and treatment of these
a common and usually severe feature of anti-neutrophil96 patients were also taken into account. Treatment was stan-
cytoplasm autoantibody (ANCA)-associated vasculitis,dardized and started after the biopsy was performed. End-
points included renal function at 18 months (GFR18), GFR18 which may lead to end-stage renal failure or death [1].
corrected for GFR0 (CORGFR18), and the occurrence of re- Renal histopathology in ANCA-associated vasculitis is
lapse or death.
typically characterized by a pauci-immune crescentic nec-Results. Parameters that most strongly correlated with GFR18
rotizing glomerulonephritis [2]. However, observationswere GFR0 (r 0.67), interstitial fibrosis (r0.45), glomeru-
losclerosis (r  0.37), and tubular atrophy (r  0.36). Pa- in a meta-analysis of 349 literary case reports suggested
rameters that most strongly correlated with CORGFR18 were that histopathology may vary considerably among these
segmental (r  0.45) and cellular (r  0.30) crescents, and patients [3]. Recently, we determined that glomerulo-
fibrinoid necrosis (r 0.46). None of the clinical and histologi-
nephritis in relation to microscopic polyangiitis or mye-cal features predicted the occurrence of relapse or death. By
loperoxidase (MPO)-ANCA positivity has more charac-applying a stepwise linear multiple regression analysis, we de-
signed a formula for the estimation of renal function at 18 teristics of chronic injury than glomerulonephritis in
months: GFR18 (mL/min)  17  0.71  GFR0 (mL/min)  relation to Wegener’s granulomatosis or proteinase-3
0.34  fibrinoid necrosis (%)  0.33  segmental crescents (PR3)-ANCA positivity. In addition, active lesions were
more abundantly present in patients with MPO-ANCA
1 Participants in EUVAS are listed in the Acknowledgments section. than in patients with PR3-ANCA [4]. It is largely un-
known which histological features are associated withKey words: ANCA-associated vasculitis, Wegener’s granulomatosis,
impaired renal function in glomerulonephritis in relationmicroscopic polyangiitis, renal biopsy, pauci-immune crescentic necro-
tizing glomerulonephritis. to ANCA-associated vasculitis.
Prognosis of glomerulonephritis in relation to ANCA-Received for publication January 29, 2002
associated vasculitis is a major concern for patients andand in revised form April 15, 2002
Accepted for publication May 30, 2002 physicians [5], especially because treatment with immu-
nosuppressive drugs—though effective in controlling dis- 2002 by the International Society of Nephrology
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Table 1. Inclusion criteria for CYCAZAREMease—is associated with severe and potentially lethal
(1, 2 and 3 are required)adverse effects [6–8]. Moreover, insight into the prognos-
1 A diagnosis of new or previously untreated MPA,tic value of disease parameters may enhance our under-
RLV, or WG with or without histological confirma-standing of the pathogenesis of this group of diseases.
tion
A number of studies on the value of candidate clinical 2 Either Renal involvement attributable to active MPA, RLV,
or WG with one or more of:and histological determinants of renal outcome have
1) elevated serum creatinineshown contradictory results [5, 9–17]. It is difficult to
2) hematuria (30 red blood cells per high powercompare these studies due to large differences in study field)
design, inclusion criteria, biopsy scoring methods, treat- 3) red cell casts
4) proteinuria (1 g/24 h)ment strategies, and the clinical end-points that were
and/or Other severe organ involvement, or imminent lossdefined. Within the framework of the European Vasculi- of vital organ function, attributable to active MPA
tis Study group (EUVAS) [18], we prospectively gath- or WG
3 ANCA-positivity; that is, one of the following possibli-ered renal biopsies with clinical information of a large
ties:group of patients with renal disease in relation to ANCA- 1) C-ANCA
associated vasculitis, of which treatment and follow-up 2) PR3-ANCA
3) MPO-ANCAwere standardized. These biopsies were scored by using a
ANCA-negativity is allowed if the disease is confirmedpreviously developed scoring protocol for renal biopsies
histologically
from patients with ANCA-associated vasculitis [19]. These
Abbreviations are in the Appendix.unique conditions enabled us to perform an elaborate
clinicopathological correlation study in which clinical
and histological predictors of outcome were determined,
and where more insight into the evolvement of renal eighteen months (GFR18), calculated by means of the
lesions over time was gained. equation for the estimation of glomerular filtration rate
as developed by Cockroft and Gault [20].
Diagnostic categories were distinguished (always withMETHODS
respect to the inclusion criteria; Table 1) by the followingPatients
criteria [18], and as such determined by the local physi-
Patients included in CYCAZAREM (a randomized cians:
trial of cyclophosphamide versus azathioprine during re- Microscopic polyangiitis. Defined as systemic vasculi-
mission of ANCA-associated vasculitis) of the European tis, predominantly affecting small vessels, with extrarenal
Systemic Vasculitis Study group (EUVAS) [18] were se- symptoms, but without airway symptoms compatible with
lected for the present clinico-histopathological study if Wegener’s granulomatosis.
a renal biopsy was performed at entry. Inclusion criteria
Renal limited vasculitis. Idiopathic, rapidly progres-
for CYCAZAREM are listed in Table 1. Exclusion crite-
sive glomerulonephritis without systemic disease mani-ria were age under 18, pregnancy, previous malignancy,
festations.known HIV-positivity, administration of any cytotoxic
Wegener’s granulomatosis. Inflammation of the respi-drug within one year before entry, hepatitis B antigen-
ratory tract together with necrotizing vasculitis affectingemia (only if HBe antigen-positive), and serum creatinine
small to medium-sized vessels.over 500 mol/L.
Indirect immunofluorescence (IIF) and enzyme-linked
immunosorbent assay (ELISA) for ANCA-testing wereTreatment
performed locally, in all participating centers. The stain-Drug regimens applied in this study are described ex-
ing pattern in the IIF test was scored as perinucleartensively elsewhere [18]. In short, all patients received
(P-ANCA), cytoplasmic (C-ANCA), atypical, or nega-the same remission induction regimen for three months,
tive. Positive sera for ANCAs directed against myeloper-consisting of oral corticosteroids and cyclophosphamide.
oxidase or proteinase-3 were reported as MPO-ANCAFollowing achievement of remission (3 to 6 months after
or PR3-ANCA, respectively.entry), patients were randomized to receive oral cortico-
Remission was defined as the complete disappearancesteroids and either cyclophosphamide or azathioprine
of clinical disease activity by using the Birmingham Vas-regimens. Patients in the cyclophosphamide limb switched
culitis Activity Score (BVAS) [21]. A major relapse re-to azathioprine after one year. All patients received taper-
quired the recurrence or first appearance of major organing doses of oral corticosteroids and azathioprine from
involvement, of sufficient severity to require treatmentone year to eighteen months after entry date.
with high dose oral corticosteroids and cyclophospha-
Study definitions mide. A minor relapse required the recurrence of disease
activity, sufficient to warrant a transient increase in ther-Renal function was defined as the glomerular filtration
rate at entry (referred to as GFR0) and at study end at apy, but not severe enough to be classified as a major re-
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lapse, and not threatening vital organ function. Patients titative candidate predictors with GFR0, GFR18 and
CORGFR18 was determined by using Pearson’s correla-who experienced either a minor or a major relapse re-
mained in the study. tion test. Correlation of quantitative candidate pre-
dictors with the occurrence of relapse or death, and the
Selection of candidate predictors correlation between categorical candidate predictors and
all five end points were assessed by Spearman’s rankClinical candidate predictors. Clinical candidate pre-
dictors were: renal function at entry (GFR0); age, gender; correlation test. For designing a model for the estimation
of GFR18 with a combination of clinical and histologicalproteinuria at entry (quantitative); diagnosis (micro-
scopic polyangiitis, /; renal limited vasculitis, /; parameters, the stepwise linear multiple regression anal-
ysis was used. Correlation coefficients were noted as ‘r’;Wegener’s granulomatosis,/); ANCA-specificity (PR3-
ANCA, /; MPO-ANCA, /); and treatment limb predictive values as “r 2.”
(cyclophosphamide vs. azathioprine as remission mainte-
nance therapy).
RESULTS
Histological candidate predictors. Paraffin sections were
Patientsstained with silver, periodic acid-Schiff (PAS), hema-
toxylin and eosin (H&E), and trichrome, and were for- Renal biopsies were performed in 132 out of 152 pa-
tients who were recruited in CYCAZAREM, of whichwarded to two of five participating pathologists (IMB,
FF, LHN, RW, JAB). Both pathologists scored the biop- 103 were received (not selected) for re-evaluation. From
this group, seven patients were excluded at entry (5 be-sies separately, were blinded to patient data and the
scores of the other observer, and according to a pre- cause cortical tissue was absent in the biopsy specimen;
2 because they did not meet the trial inclusion criteria).viously standardized protocol for scoring renal biopsies
of patients with ANCA-associated vasculitis [17, 19]. In During follow-up, six patients were withdrawn (own
wish; ischemic cerebrovascular accident; therapy intoler-short, each glomerulus had to be scored separately for
the presence of fibrinoid necrosis, crescents (cellular/ ance; hepatitis B; diabetes mellitus; and dialysis depen-
dency in the first trial week), three were lost to follow-fibrous and segmental/circumferential), sclerosis (local,
segmental, or global), or any other lesion. Periglomerular up, and five patients died (2 from pneumonia; 1 sudden
death due to myocardial infarction or stroke; 1 adult respi-infiltrates and granulomatous reactions were scored as
well. The amount of glomerular lesions was expressed ratory distress syndrome; and 1 non-ischemic cerebrovas-
cular accident). This meant that GFR0 and GFR18 wereas a percentage of the total number of glomeruli for each
biopsy. Most interstitial, tubular, and vascular lesions available from 96 and 82 patients, respectively. The
GFR18 of four patients that were dialysis dependent atwere scored qualitatively, except for granulomas (num-
ber), interstitial infiltrates (///), interstitial study end was considered zero. Diagnostic categories were
microscopic polyangiitis (N 33), renal limited vasculitisfibrosis (//), and tubular atrophy (//),
which were scored semiquantitatively. In total, 39 histo- (N  11), and Wegener’s granulomatosis (N  52).
ANCA-test results are listed in Table 2. Patients includedlogical parameters were examined. The scores were en-
tered into a central database (MSAccess), and discrepan- 54% females and 46% males, with a mean age of 56
years (range 21 to 77). Of the 96 patients who werecies between the observers were resolved by conference
during central review sessions, achieving consensus for included, 89 (93%) achieved remission. Of the 82 pa-
tients that could be followed for 18 months, 36 had beeneach biopsy.
randomized to azathioprine and 46 to cyclophosphamide
Clinical end points and statistics as the remission maintenance therapy. Mean GFR0 and
GFR18 (after a mean of 18  1.5 months) were 43 mL/Clinical end points in this study were GFR0, GFR18,
the occurrence of a relapse, or death. As renal function min and 61 mL/min, respectively. The mean maximal
GFR during follow-up was 62 mL/min.at entry has been shown to be a major predictor of renal
outcome in a number of renal diseases [5, 22, 23], we
Predictors for GFR0also wanted to investigate the correlation of both clinical
and histological parameters with GFR18 after correction The correlations between histological features and
GFR0 are listed in Table 3. Poor correlation was obtainedfor GFR0. The latter value was expressed as the corrected
GFR18 (CORGFR18), defined by the difference between for the histological parameters excluded from Table 3.
The percentage of normal glomeruli was the strongestthe observed GFR18 and its linear prediction based upon
GFR0. This correction makes the corrected value statisti- predictor of GFR0, with higher GFR0 in those patients
whose biopsy had shown the highest percentages of nor-cally independent from the starting value [24].
The computer program used to perform statistical mal glomeruli. The percentage of glomeruli with cres-
cents showed a relationship with GFR0, which is illus-analyses was the SPSS 9.0 standard version for Windows
(SPSS, Inc., Chicago, IL, USA). Correlation of the quan- trated for cellular crescents in Figure 1A. The percentage
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Table 2. ANCA-test results of these clinical parameters showed even a moderate
relationship with CORGFR18, meaning there was noDiagnosis N
baseline renal function independent influence on GFR18.IIF ELISA MPA RLV WG
Neither treatment limb nor the level of proteinuria at
P-ANCA MPO-ANCA 15 8 7
entry predicted for GFR18 or for CORGFR18.PR3-ANCA 1 0 0
MPO-ANCA & PR3-ANCA 1 0 0 Four distinct patterns were observed for the correla-
Negative 0 0 0 tion of renal histology with GFR18 and CORGFR18. Firstly,Not reported 4 2 1
the percentage of glomeruli with crescents, segmentalC-ANCA MPO-ANCA 0 0 0
PR3-ANCA 6 0 29 crescents, and cellular crescents (Fig. 1), and the pres-
MPO-ANCA & PR3-ANCA 0 0 2 ence of tubular intra-epithelial infiltrates all correlated
Negative 0 0 3
positively with CORGFR18, but did not predict for GFR18,Not reported 5 1 6
Atypical ANCA MPO-ANCA 1 0 0 which means that these lesions predict for GFR18 inde-
PR3-ANCA 0 0 0 pendent of GFR0. Secondly, the percentage of glomeruliMPO-ANCA & PR3-ANCA 0 0 0
with fibrinoid necrosis (Fig. 2) correlated positively withNegative 0 0 0
Not reported 0 0 0 GFR18 and CORGFR18, being the best GFR0-indepen-
Negative MPO-ANCA 0 0 0 dent predictor for GFR18. Thirdly, (global) glomerulo-PR3-ANCA 0 0 0
sclerosis was a strong predictor of GFR18 (Fig. 3). TheMPO-ANCA & PR3-ANCA 0 0 0
Negative 0 0 1 negative correlation of this lesion with GFR18 appeared
Not reported 0 0 2 to be only partly GFR0-independent, as a much weakerNot reported MPO-ANCA 0 0 0
relationship of glomerulosclerosis with CORGFR18 wasPR3-ANCA 0 0 0
MPO-ANCA & PR3-ANCA 0 0 1 observed. Finally, the extent of interstitial infiltrates, in-
Negative 0 0 0 terstitial fibrosis (Fig. 4), and tubular atrophy, and the
Not reported 0 0 0
percentage of normal glomeruli were all predictors for
Abbreviations are in the Appendix.
GFR18, but this correlation appeared to be almost en-
tirely dependent of GFR0 as correlations of these lesions
with CORGFR18 were negligible.
of glomeruli with fibrinoid necrosis was not related to
Predictors for relapses and deathsGFR0 (Fig. 2A). Other histological features that showed
a relationship with GFR0 were the percentage of glomer- Nine patients experienced a relapse. Five patients died,
three of whom the cause of death was probably treatmentulosclerosis (Fig. 3A), and the extent of interstitial infil-
trates, interstitial fibrosis (Fig. 4A), tubular atrophy, tu- related (see above). None of the clinical and histological
features at entry predicted for relapse or death duringbular casts, tubular necrosis, and tubular intra-epithelial
infiltrates. eighteen months of follow-up (data not shown).
Combination of predictors as a prognostic toolPredictors for GFR18 and CORGFR18
GFR0 was the best predictive parameter for GFR18 in By using a stepwise linear multiple regression analysis,
a model for the estimation of renal function at eighteenthis study (r  0.673, P  0.001; Fig. 5 and Table 3). In
other words, patients with high GFR0 had more favorable months was designed. It is statistically irrational to in-
clude all parameters in a linear regression analysis if therenal outcome than patients with low GFR0. Renal func-
tion had improved by more than 5 mL/min in 64% of number of variables is high (48 in the present study) and
the number of cases relatively low (96 in the presentpatients, had deteriorated by more than 5 mL/min in
18%, and remained unchanged in 18%. Four patients study). To prevent the occurrence of so-called “over-fit-
ting,” the number of variables should be lower than onewith GFR0 between 10 and 25 mL/min became dialysis
dependent. However, many other patients with a low tenth of the number of cases. We therefore limited the
number of variables taken into account in the regressionGFR0 had clearly improved GFR18. Glomerulosclerosis
in 100% of the glomeruli was observed in the renal biop- analysis, by including GFR0 (as it was the most powerful
predictor for GFR18) and those variables that showedsies (performed at entry) from two of these dialysis de-
pendent patients, and in none of the other patients that reasonable correlations with CORGFR18: the percentage
of glomeruli with fibrinoid necrosis, crescents (segmen-were followed during eighteen months. Two other pa-
tients also had 100% glomerulosclerosis at entry, but tal, cellular, and segmental cellular) and (global) glomer-
ulosclerosis, and the presence of interstitial edema andone of these patients was withdrawn from the study be-
cause of dialysis dependency in the first trial week, and tubular intra-epithelial infiltrates.
The optimal model for the prediction of GFR18 in-the other patient died from either myocardial infarction
or stroke, also in the first trial week. Other clinical pre- cluded a constant value, GFR0, the percentage of glomer-
uli with fibrinoid necrosis, and the percentage of glomer-dictors for GFR18 were age and diagnosis. However, none
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Table 3. Correlation of clinical and histological features with GFR0, GFR18, and CORGFR18
GFR0 GFR18 CORGFR18
r P r P r P
GFR0 1.000 0.001 0.673 0.001 0.000 1.000
Clinical variables
Gender a 0.061 0.557 0.170 0.126 0.098 0.382
Age 0.371 0.001 0.379 0.001 0.198 0.075
Microscopic polyangiitis (/) 0.323 0.001 0.255 0.021 0.036 0.747
Renal limited vasculitis (/) 0.125 0.225 0.116 0.301 0.063 0.576
Wegener’s granulomatosis (/) 0.398 0.001 0.271 0.014 0.006 0.930
Proteinuria 0.227 0.035 0.047 0.688 0.105 0.372
PR3-ANCA (/) 0.295 0.004 0.238 0.031 0.058 0.606
MPO-ANCA (/) 0.306 0.002 0.192 0.084 0.035 0.754
Treatment limbb 0.224 0.043 0.048 0.671 0.140 0.211
Glomerular lesions
No abnormalities 0.526 0.001 0.312 0.004 0.041 0.717
Fibrinoid necrosis 0.111 0.281 0.309 0.005 0.464 0.001
Crescents 0.295 0.003 0.012 0.912 0.293 0.007
Circumferential crescents 0.209 0.041 0.164 0.140 0.001 0.992
Segmental crescents 0.198 0.053 0.205 0.065 0.446 0.001
Cellular crescents 0.275 0.007 0.029 0.796 0.301 0.006
Fibrous crescents 0.091 0.380 0.059 0.600 0.006 0.959
Glomerulosclerosis 0.297 0.003 0.422 0.001 0.307 0.005
Global sclerosis 0.290 0.004 0.430 0.001 0.321 0.003
Granulomatous reactions 0.179 0.081 0.206 0.063 0.133 0.233
Interstitial lesions
Interstitial edema 0.175 0.087 0.062 0.577 0.166 0.136
Interstitial infiltrates 0.392 0.001 0.346 0.001 0.046 0.683
Interstitial fibrosis 0.482 0.001 0.449 0.001 0.059 0.601
Tubular casts 0.287 0.005 0.262 0.018 0.023 0.836
Tubular necrosis 0.379 0.001 0.169 0.128 0.173 0.121
Tubular atrophy 0.373 0.001 0.358 0.001 0.049 0.665
Intra-epithelial infiltrates 0.343 0.001 0.110 0.324 0.222 0.045
a Female was coded ‘1’ and male was coded ‘2’ in our analyses
b Azathioprine was coded ‘1’ and cyclophophamide was coded ‘2’ in our analyses
uli with segmental crescents. A formula for the optimal uli (5) would influence our results, but this was not the
case (data not shown).estimation of GFR18 was calculated as:
Estimated GFR18 (mL/min)  17 
DISCUSSION
0.71  GFR0 (mL/min) 
The results of a prospective multicenter study of 96
0.34  fibrinoid necrosis (%)  patients with moderate renal disease (serum creatinine
500 mol) in relation to ANCA-associated vasculitis,0.33  segmental crescents (%) [Eq. 1]
including clinical and histological predictors of outcome,
(r 2  0.602; standard deviation  19.07 mL/min). are presented.
The relationship between the estimated GFR18 and In the present study, GFR0 was the best predictor of
the measured GFR18 is visualized in Figure 6. By means GFR18. Baseline renal function as a potent predictor for
of the test for the presence of statistical interaction in renal outcome was previously described in retrospective
analysis of covariance (ANCOVA), we assessed whether studies on renal disease in association with ANCA-asso-
the formula for the estimation of renal function at ciated vasculitis, but to our knowledge, we are the first
eighteen months depended on diagnosis, ANCA-speci- to report this phenomenon in a prospective study with
ficity, or treatment limb, but this was not the case (data standardized treatment and follow-up [5, 25–27]. To de-
not shown). termine the influence of several parameters on renal
outcome independent of GFR0, we used a corrected
Sample size value of GFR18, the CORGFR18. Crescents, in particular
Reported results are based on analyses without a mini- segmental crescents and cellular crescents, and not cir-
mum for the number of glomeruli in the biopsies (biop- cumferential or fibrous crescents, and tubular intra-epi-
sies without cortical tissue were excluded). We tested thelial infiltrates—all regarded as being associated with
active disease—were shown to have a GFR0-independentwhether the presence of only a small number of glomer-
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Fig. 1. Scatter plots with regression line for the percentage of cellular
crescents versus baseline glomerular filtration rate (GFR0; A), GFR at
18 months (GFR18; B), and corrected GFR at 18 months (CORGFR18;
C ). In panel A, r  0.275, P  0.007; in B, r  0.029, P  0.796; in
C, r  0.301, P  0.006.
positive correlation with GFR18. This means that these necrosis with GFR0, GFR18, and CORGFR18, attracts spe-
cial attention in this clinico-histopathological study. De-lesions are somehow related to renal function recovery,
for example, induced by therapy, and therefore, that they spite our finding that the extent of fibrinoid necrosis was
not related to GFR0, the lesion was a strong predictor formay be reversible to a certain extent. Our finding that
in contrast to fibrous crescents, cellular and segmental GFR18 and CORGFR18. One could argue that its positive
predictive value is epiphenomenal to the positive pre-crescents correlated with CORGFR18, supports the hy-
pothesis that there may be a certain point of no return dictive value of cellular and segmental crescents. How-
ever, after correction for the latter lesions, fibrinoid ne-after which a crescentic glomerulus loses its potential of
recovering to a histologically normal glomerulus [28]. In crosis remained predictive for GFR18 and CORGFR18
(data not shown). Our results suggest that the evolutiona model of crescentic glomerulonephritis in the rabbit,
90% of the glomeruli were crescentic at the onset of the of crescentic glomeruli is dependent on the co-occur-
rence of fibrinoid necrosis in the same glomerulus. In aexperiment, whereas in follow-up biopsies after 45 days
approximately 50% of glomeruli showed histologically previous study, in which a topographical reconstruction
of the distribution of crescents and fibrinoid necrosisnormal glomeruli and global sclerosis of the other 50%
[29]. Alternatively, assuming irreversibility, these lesions in affected glomeruli was made by means of a three-
dimensional reconstruction, we already suggested thatmay heal while leaving a minimum of damage, for exam-
ple, a fibrous capsule that may be found after the cellular crescents in Wegener’s granulomatosis could develop
with and without the co-occurrence of fibrinoid necrosiscrescent has resolved [30].
Another point of consideration concerning the evolu- [31]. Composition (in terms of cell type, matrix mole-
cules, and adhesion molecules) of these two types oftion of crescents involves the role of fibrinoid necrosis
in the crescentic glomerulus. The correlation of fibrinoid crescents may be different, as was previously suggested
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Fig. 2. Scatter plots with regression line for the percentage of glomeruli
with fibrinoid necrosis versus GFR0 (A), GFR18 (B), and CORGFR18
(C ). In panel A, r  0.111, P  0.281; in B, r 0.309, P  0.005; in
C, r  0.464, P  0.001.
[32], and may reflect two different pathways of crescent EUVAS, this issue will be further studied in patients
with more severe renal involvement (serum creatininedevelopment and evolution in ANCA-associated vascu-
litis. This issue should be investigated. 500 mol/L).
Interstitial fibrosis and tubular atrophy were stronglyThe strong and negative correlation between glomeru-
losclerosis and GFR18 was only partly GFR0-indepen- and negatively correlated with GFR18, but this relation-
ship was not GFR0-independent. These results suggestdent. Accordingly, glomerulosclerosis somehow promotes
the development of further abnormalities that negatively that the extent of interstitial fibrosis and tubular atrophy,
while highly predictive for GFR18, is not subjected to ainfluence GFR18. Non-sclerotic glomeruli may compen-
sate the loss of filtration surface by glomerular hemody- change in either direction, and that it represents damage
that has been caused before the initiation of treatment.namic adaptation [33, 34]. Intraglomerular pressure in
these hypertrophic glomeruli will be high as compared Although an increase in the extent of these lesions may
be possible, progression of interstitial fibrosis and tubularto that in normal glomeruli, which engenders the devel-
opment of new glomerulosclerotic lesions. Glomerulo- atrophy is probably prevented by adequate treatment.
To our knowledge, a decrease in the extent of thesesclerosis in 100% of glomeruli was observed in the renal
biopsies of four patients; three went into end-stage renal lesions has never been demonstrated.
We previously reported that the percentage of normaldisease and one died of myocardial infarction or stroke.
It may be questionable whether immunosuppressive glomeruli was predictive for renal function, both at the
time of biopsy and during follow-up [17]. Similarly, thetreatment should be initiated in these patients for the
purpose of recovery of renal function. Of course, immu- present study reveals a correlation of the percentage of
normal glomeruli with GFR0 and GFR18. In the presentnosuppressive treatment may be needed if active extra-
renal vasculitis is present. Within the framework of the study, however, it was additionally observed that the cor-
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Fig. 3. Scatter plots with regression line for the percentage of sclerotic
glomeruli versus GFR0 (A), GFR18 (B), and CORGFR18 (C ). In panel
A, r  0.297, P  0.003; in B, r  0.422, P  0.001; in C, r 
0.307, P  0.005.
relation of the percentage of normal glomeruli with ment. Caution should be observed when drawing conclu-
sions from this formula for at least two reasons. Firstly,GFR18 was not GFR0-independent.
The main trial report on the CYCAZAREM data re- our study cohort comprised only patients with baseline
serum creatinine lower than 500 mol/L, and extrapola-vealed that outcome in the two remission maintenance
therapy limbs (azathioprine vs. cyclophosphamide) was tion of our equation to patients with baseline serum
creatinine over 500 mol/L does not seem to be advis-identical (abstract; Jayne et al, J Am Soc Nephrol 10:A0540,
1999) [35]. Similarly, for the subgroup of CYCAZAREM- able, as renal function of the latter patients is on the edge
of dialysis dependency. Secondly, the predictive value ofpatients included in the present study, there was no corre-
lation to treatment limb for either GFR18 or CORGFR18. our equation is limited (r 2 0.602). Nevertheless, despite
these drawbacks, the formula does show that renal histol-This issue is extensively discussed in the CYCAZAREM
report. ogy in combination with baseline renal function is a much
better predictor for renal outcome at eighteen monthsAn analysis of the independent influence of antihyper-
tensive drugs on outcome was not investigated in our cur- than baseline renal function only.
In summary, we present a clinico-histopathologicalrent study. Nevertheless, the possible differences in anti-
hypertensive strategies probably do not interfere with analysis of 96 patients with renal disease in relation to
ANCA-associated vasculitis in which we determined thethese results, as the use of antihypertensive drugs is likely
to be distributed equally due to the size of the study. predictors of outcome. Our combination of a prospective
study design, the size and homogeneity of the study co-By using a stepwise linear multiple regression analysis,
we designed a formula for the estimation of renal func- hort, the accurate scoring system, and the standard treat-
ment guaranteed favorable conditions for such a study.tion at eighteen months. This formula was similar for
groups defined by diagnosis, ANCA-specificity, or treat- Our data suggest that, in ANCA-associated glomerulo-
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Fig. 4. Box plots for the severity of interstitial fibrosis versus GFR0
(A), GFR18 (B), and CORGFR18 (C ). In panel A, r  0.482, P 
0.001; in B, r  0.449, P  0.001; in C, r  0.059, P  0.601.
Fig. 6. Scatter plot of the estimated GFR18 versus the measured GFR18
(r2  0.602, SD  19.07 mL/min). The estimated GFR18 was calculated
by the following formula: Estimated GFR18 (mL/min)  17  0.71 
GFR0 (mL/min)  0.34  fibrinoid necrosis (%)  0.33  segmentalFig. 5. Scatter plot with regression line for GFR0 versus GFR18 (r 
0.673, P  0.001). crescents (%).
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